Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.95 and traded as high as $0.93. Sunesis Pharmaceuticals shares last traded at $0.92, with a volume of 14,186 shares traded.

Several analysts recently issued reports on SNSS shares. HC Wainwright reiterated a “hold” rating and set a $1.50 target price on shares of Sunesis Pharmaceuticals in a research report on Friday, August 9th. Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Sunday, June 16th. Finally, ValuEngine upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $2.92.

The firm has a market cap of $103.53 million, a PE ratio of -1.27 and a beta of 2.74. The firm has a fifty day simple moving average of $0.84 and a two-hundred day simple moving average of $0.95. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.27 and a current ratio of 2.27.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Equities analysts forecast that Sunesis Pharmaceuticals, Inc. will post -0.4 EPS for the current fiscal year.

In other news, major shareholder Aisling Capital Iv, Lp purchased 2,500,000 shares of the business’s stock in a transaction on Monday, July 15th. The stock was acquired at an average price of $0.60 per share, for a total transaction of $1,500,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 4.22% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNSS. Aisling Capital Management LP lifted its stake in shares of Sunesis Pharmaceuticals by 192.3% in the 1st quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock valued at $9,234,000 after purchasing an additional 5,000,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Sunesis Pharmaceuticals by 228.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,283,383 shares of the biopharmaceutical company’s stock valued at $1,660,000 after purchasing an additional 1,587,157 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Sunesis Pharmaceuticals in the 2nd quarter valued at approximately $1,018,000. Wells Fargo & Company MN lifted its stake in shares of Sunesis Pharmaceuticals by 42.7% in the 2nd quarter. Wells Fargo & Company MN now owns 1,341,151 shares of the biopharmaceutical company’s stock valued at $975,000 after purchasing an additional 401,193 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Sunesis Pharmaceuticals by 257.3% in the 2nd quarter. BlackRock Inc. now owns 783,059 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 563,924 shares during the last quarter. Institutional investors and hedge funds own 32.85% of the company’s stock.

Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Further Reading: What is an economic bubble?

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.